A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04) Meeting Abstract
| Authors: | Zaman, K.; Modi, S.; Ohtan, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A. |
| Abstract Title: | A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04) |
| Meeting Title: | 2020 Swiss Oncology and Hematology Congress (SOHC) |
| Journal Title: | Swiss Medical Weekly |
| Volume: | 150 |
| Issue: | Suppl. 247 |
| Meeting Dates: | 2020 Nov 18-21 |
| Meeting Location: | Virtual |
| ISSN: | 1424-7860 |
| Publisher: | E M H Swiss Medical Publishers Ltd |
| Date Published: | 2020-11-17 |
| Start Page: | 28 S |
| End Page: | 29 S |
| Language: | English |
| ACCESSION: | WOS:000592781900068 |
| PROVIDER: | wos |
| PUBMED: | 33200807 |
| DOI: | 10.4414/smw.2020.20411 |
| Notes: | Meeting Abstract: P48 -- Source: Wos |
